TargetMol

Dermorphin

Product Code:
 
TAR-T7404
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T7404-2mg2mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7404-5mg5mg£153.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7404-10mg10mg£211.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7404-25mg25mg£352.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7404-50mg50mg£549.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7404-100mg100mg£777.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Dermorphin is agonist of μ-opioid receptor (MOR) agonist.
CAS:
77614-16-5
Formula:
C40H50N8O10
Molecular Weight:
802.886
Pathway:
Neuroscience; Endocrinology/Hormones; GPCR/G Protein
Purity:
0.98
SMILES:
CC(NC(=O)C(N)Cc1ccc(O)cc1)C(=O)NC(Cc1ccccc1)C(=O)NCC(=O)NC(Cc1ccc(O)cc1)C(=O)N1CCCC1C(=O)NC(CO)C(N)=O
Target:
Opioid Receptor

References

Robinson M A , Guan F , Mcdonnell S , et al. Pharmacokinetics and pharmacodynamics of dermorphin in the horse[J]. Journal of Veterinary Pharmacology and Therapeutics, 2015, 38(4):321-329. Tiwari V , Yang F , He S Q , et al. Activation of Peripheral ?-opioid Receptors by Dermorphin [D-Arg2, Lys4] (1-4) Amide Leads to Modality-preferred Inhibition of Neuropathic Pain.[J]. Anesthesiology, 2016, 124(3):706.